


## (Rac)-Vazegepant-<sup>13</sup>C,<sub>3</sub>D<sub>3</sub>

Cat. No.:	HY-134992S
Molecular Formula:	C <sub>35</sub> <sup>13</sup> CH <sub>43</sub> D <sub>3</sub> N <sub>8</sub> O <sub>3</sub>
Molecular Weight:	642.81
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

(Rac)-Vazegepant-<sup>13</sup>C,<sub>3</sub>D<sub>3</sub> is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine<sup>[1][2]</sup>.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. *J Med Chem*. 2020 Mar 26;63(6):2915-2929.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA